Advertisement

Advertisement

JP:520A Stock Latest News

J-Pharma Launches Restricted Stock Compensation for Directors and Executives

Company AnnouncementsJ-Pharma Launches Restricted Stock Compensation for Directors and Executives

J-Pharma Advances Global Oncology Pipeline With Lead Drug Nanvuranlat

PremiumCompany Announcements

J-Pharma Advances Global Oncology Pipeline With Lead Drug Nanvuranlat

25d ago

J-Pharma to Restructure Capital Surplus to Eliminate Retained Earnings Deficit

PremiumCompany Announcements

J-Pharma to Restructure Capital Surplus to Eliminate Retained Earnings Deficit

2M ago

J-Pharma to Introduce Restricted Stock Plan to Align Directors With Shareholders

PremiumCompany Announcements

J-Pharma to Introduce Restricted Stock Plan to Align Directors With Shareholders

2M ago

J-Pharma Overhauls Board and Creates CBO Role to Drive Global Growth

PremiumCompany Announcements

J-Pharma Overhauls Board and Creates CBO Role to Drive Global Growth

2M ago

J-Pharma Flags Risks and Uncertainty in FY2026 Earnings Presentation

PremiumCompany AnnouncementsJ-Pharma Flags Risks and Uncertainty in FY2026 Earnings Presentation

2M ago

J‑Pharma Advances Nanvuranlat Into Pivotal Biliary Tract Cancer Trial: What Investors Should Watch

Company Announcements

J‑Pharma Advances Nanvuranlat Into Pivotal Biliary Tract Cancer Trial: What Investors Should Watch

2M ago

J-Pharma Books Over JPY 1 Billion in AMED Grant Income for MS Drug R&D

Company Announcements

J-Pharma Books Over JPY 1 Billion in AMED Grant Income for MS Drug R&D

2M ago

J-Pharma Widens Annual Loss but Bolsters Equity and Cash to Fund R&D

PremiumCompany Announcements

J-Pharma Widens Annual Loss but Bolsters Equity and Cash to Fund R&D

2M ago

J‑Pharma’s JPH034 Phase 1 Trial: Early Safety Data in Focus for Investors

PremiumCompany Announcements

J‑Pharma’s JPH034 Phase 1 Trial: Early Safety Data in Focus for Investors

3M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >